{"id":737,"date":"2019-05-30T15:20:47","date_gmt":"2019-05-30T19:20:47","guid":{"rendered":"https:\/\/research.ncsu.edu\/win\/?p=737"},"modified":"2024-01-08T16:19:03","modified_gmt":"2024-01-08T21:19:03","slug":"emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa","status":"publish","type":"post","link":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/","title":{"rendered":"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA<\/a>"},"content":{"rendered":"\n\n\n\n

DURHAM, N.C., May 30, 2019 \/PRNewswire\/ — Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of Directors. Jack Bailey, President, US Pharmaceuticals at GlaxoSmithKline, joined the Board on May 17, 2019. Moise Khayrallah, PhD, CEO and Chairman of the Board, Meg Powell, PharmD, Co-Founder of Target Pharma Solutions, and Bobby Helmedag, Managing Director, Rex Health Ventures, will continue to serve with Bailey.<\/p>\n

“We are thrilled to have Jack at the table with us and look forward to his contributions in driving Emergo Therapeutics to success. Jack’s addition to our board is a strong signal of good things to come from our team here at Emergo. With Jack’s help, we will continue to meet and exceed our aggressive internal timelines for the development of our lead compound, norketotifen, for influenza and influenza-like illness (ILI),” Dr. Khayrallah said.<\/p>\n

Jack Bailey commented on the appointment, “Moise has assembled an excellent team that is focused around our common goal. I am excited to join my fellow board members and offer my support in moving Emergo Therapeutics closer to the goal of providing some relief to patients.”<\/p>\n

About Emergo Therapeutics<\/p>\n

Emergo Therapeutics (http:\/\/emergotherapeutics.com\/) is focused on developing drugs that reduce inflammation and improve immune system function in various indications, starting with infectious diseases. Emergo’s lead program is the development of norketotifen for the treatment of uncomplicated influenza and influenza\u2011like illness (ILI).<\/p>\n

Contact:<\/p>\n

Henry (Hank) McCarthy II
\nVice President, Business Development
\nEmergo Therapeutics, Inc.
\n6208 Fayetteville Road, Suite 104
\nDurham, NC 27713
\n+1 (984) 377-5151<\/p>\n

SOURCE Emergo Therapeutics<\/p>\n

Related Links
\nhttp:\/\/emergotherapeutics.com<\/p>","protected":false},"excerpt":{"rendered":"

DURHAM, N.C., May 30, 2019 \/PRNewswire\/ — Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of…<\/p>\n","protected":false},"author":1119,"featured_media":113,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":true,\"showDate\":true,\"showFeaturedVideo\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[9],"tags":[56,39,65,12,42,21,75,59,47],"class_list":["post-737","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-angel-investing","tag-angel-network","tag-emergo-therapeutics","tag-entrepreneurship","tag-investing","tag-nc-state","tag-nc-state-university","tag-north-carolina-startups","tag-wolfpack-investor-network"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\nEmergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA - Wolfpack Investor Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA - Wolfpack Investor Network\" \/>\n<meta property=\"og:description\" content=\"DURHAM, N.C., May 30, 2019 \/PRNewswire\/ — Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"Wolfpack Investor Network\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-30T19:20:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-08T21:19:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1043\" \/>\n\t<meta property=\"og:image:height\" content=\"522\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Staff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Staff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/\",\"url\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/\",\"name\":\"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA - Wolfpack Investor Network\",\"isPartOf\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\",\"datePublished\":\"2019-05-30T19:20:47+00:00\",\"dateModified\":\"2024-01-08T21:19:03+00:00\",\"author\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf\"},\"breadcrumb\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#primaryimage\",\"url\":\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\",\"contentUrl\":\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\",\"width\":1043,\"height\":522},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/research.ncsu.edu\/win\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/#website\",\"url\":\"https:\/\/research.ncsu.edu\/win\/\",\"name\":\"Wolfpack Investor Network\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/research.ncsu.edu\/win\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf\",\"name\":\"Staff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3f69be4b8f7e5a1f53de8f6e0308060c17302ed08fc14c74cf2ad61146c4e097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3f69be4b8f7e5a1f53de8f6e0308060c17302ed08fc14c74cf2ad61146c4e097?s=96&d=mm&r=g\",\"caption\":\"Staff\"},\"url\":\"https:\/\/research.ncsu.edu\/win\/author\/staff\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA - Wolfpack Investor Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/","og_locale":"en_US","og_type":"article","og_title":"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA - Wolfpack Investor Network","og_description":"DURHAM, N.C., May 30, 2019 \/PRNewswire\/ — Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of…","og_url":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/","og_site_name":"Wolfpack Investor Network","article_published_time":"2019-05-30T19:20:47+00:00","article_modified_time":"2024-01-08T21:19:03+00:00","og_image":[{"width":1043,"height":522,"url":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","type":"image\/png"}],"author":"Staff","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Staff","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/","url":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/","name":"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA - Wolfpack Investor Network","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/win\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","datePublished":"2019-05-30T19:20:47+00:00","dateModified":"2024-01-08T21:19:03+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#primaryimage","url":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","contentUrl":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","width":1043,"height":522},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/win\/emergo-therapeutics-board-of-directors-welcomes-jack-bailey-president-gsk-pharmaceuticals-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/win\/"},{"@type":"ListItem","position":2,"name":"Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/win\/#website","url":"https:\/\/research.ncsu.edu\/win\/","name":"Wolfpack Investor Network","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/win\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf","name":"Staff","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3f69be4b8f7e5a1f53de8f6e0308060c17302ed08fc14c74cf2ad61146c4e097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3f69be4b8f7e5a1f53de8f6e0308060c17302ed08fc14c74cf2ad61146c4e097?s=96&d=mm&r=g","caption":"Staff"},"url":"https:\/\/research.ncsu.edu\/win\/author\/staff\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts\/737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/users\/1119"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/comments?post=737"}],"version-history":[{"count":1,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts\/737\/revisions"}],"predecessor-version":[{"id":1862,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts\/737\/revisions\/1862"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/media\/113"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/media?parent=737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/categories?post=737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/tags?post=737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}